Michael J. Rogers

Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras

Steven P. Luckman, D. E. Hughes, Fraser P. Coxon et al. · Journal of Bone and Mineral Research · 1998 · 1.2K citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates

James E. Dunford, Keith Thompson, Fraser P. Coxon et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 896 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Cellular and molecular mechanisms of action of bisphosphonates

Michael J. Rogers, Sharon Gordon, Helena L. Benford et al. · Cancer · 2000 · 712 citations · Full text

Medicine, Cell Biology, Molecular Biology +12

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation <i>in vitro</i>

John Fisher, Michael J. Rogers, J. M. Halasy et al. · Proceedings of the National Academy of Sciences · 1999 · 679 citations

Medicine, Biochemistry, Pharmacology +17

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

K.L. Kavanagh, Kunde Guo, James E. Dunford et al. · Proceedings of the National Academy of Sciences · 2006 · 532 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17